PwC pre­dicts 'flur­ry' of $5B to $15B biotech deals in 2023

PwC’s phar­ma in­dus­try trends analy­sis is here — and the au­dit com­pa­ny is pre­dict­ing sev­er­al neg­a­tives amid mod­est ex­pec­ta­tions for M&A, cov­er­ing every­thing from high in­fla­tion and ris­ing cap­i­tal costs to in­creased FTC scruti­ny, just to name a few.

The re­port rec­om­mends lead­ers fo­cus on four key ar­eas: dig­i­tiz­ing the val­ue chain, “get­ting fit for growth” by re­think­ing where they al­lo­cate funds, find­ing ways to adapt to pres­sure on drug pric­ing and “win­ning” in M&A.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.